openPR Logo
Press release

Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

10-16-2017 09:16 AM CET | Health & Medicine

Press release from: Arizton Advisory & Intelligence

Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline HDAC inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information about discontinued and dormant drugs.

View details: https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights

Some of the key HDAC inhibitors currently available in market are Zolinza (vorinostat), Epidaza (chidamide), and Beleodaq (belinostat) for the treatment of ovarian cancer, acute myelogenous leukemia, non small cell lung cancer, Non-Hodgkin’s lymphoma, hematological malignancies, multiple myeloma, renal cell carcinoma, melanoma, pancreatic cancer, breast cancer, and graft versus host disease. HDAC pipeline too is quite robust with more than 40 molecules in various stages of clinical development. Few of the key pipeline HDAC inhibitors include entinostat, pracinostat (SB939), abexinostat, CHR-5154, CKD-581, RG2833, MPT0E028, and CS3158. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-Clinical stage.

Few of the companies which are involved in the development of HDAC inhibitor are Chipscreen, Celgene, Syndax, AbbVie, Merck, Novartis, Celldex, GSK, Chroma, and Onxeo. There are numerous factors of HDAC inhibitor which would help in the growth of market and also continue the impact of these inhibitors in the market.

Reasons to Buy

To gain erudite insights about the HDAC inhibitor pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

Order a report now: https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights

Related Reports

1) Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/tumor-necrosis-factor-alpha-tnf-a-inhibitors-pipeline-insights

2) Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/anaplastic-lymphoma-kinase-alk-inhibitors-pipeline-insights

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017 here

News-ID: 774128 • Views: 360

More Releases from Arizton Advisory & Intelligence

Denmark Data Center Market Size by Investment to Reach USD 2.5 Billion by 2025 …
In-depth analysis and data-driven insights on the impact of COVID-19 included in this Denmark data center market report. Denmark data center market size is expected to grow at a CAGR of 1.7% during the period 2019−2025. Key Highlights Offered in the Report: 1. District heating, renewable energy, allocation of power, and land for data center is making Denmark an attractive location for data center investments. 2. Hyperscale data center development by Facebook and
Urinary Catheters Market Size to Reach Revenues of USD 2.5 Billion in 2020 – A …
The global urinary catheters market is expected to grow at a CAGR of over 5% during the period 2019−2025. Key Highlights Offered in the Report: 1. The growing prevalence of urinary incontinence and urine retention is boosting the global urinary catheters market, resulting in an incremental growth of around USD 959 million during the forecast period. 2. The usage of urinary catheters among men is increasing, resulting in an incremental growth
Hematology Testing Market Size to Reach Revenues of USD 5.4 Billion by 2025 – …
The global hematology testing market is expected to grow at a CAGR of approximately 5% during the period 2019−2025. Key Highlights Offered in the Report: 1. The US accounted for the major share of the global hematology testing market and likely to witness incremental growth of around USD 306 million during the forecast period. 2. The consumables segment accounted for the major share in the market with incremental growth of more than
Home Gym Equipment Market Size to Reach Revenues of around USD 31 Billion by 202 …
In-depth analysis and data-driven insights on the impact of COVID-19 included in this global home gym equipment market report. The global home gym equipment market is expected to grow at a CAGR of 8.5% during the period 2019−2025. Key Highlights Offered in the Report: 1. High gym dropout rate in APAC countries and technological advancements in home gym equipment is propelling the demand for home gym equipment in the market. 2. The gradual

All 5 Releases


More Releases for HDAC

HDAC Inhibitors Market - Future and Technological Advancement 2026
HDAC inhibitors refers to the class of anti-cancer agents that play a vital role in non-epigenetic or epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone deacetylase inhibitors (HDACi) are promising therapeutics, which have already shown potential for oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Vorinostat (Merck & Co. Inc.) is a novel drug used in the management of cutaneous T cell
HDAC Inhibitors Market - Trends and Opportunities 2017 - 2025
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur
Global Histone Deacetylase(HDAC) Inhibitors Market 2017 - SpeBio, Onyx, Quimatry …
Apex Market Reports, recently published a detailed market research study focused on the "Histone Deacetylase(HDAC) Inhibitors Market" across the global, regional and country level. The report provides 360° analysis of "Histone Deacetylase(HDAC) Inhibitors Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Histone Deacetylase(HDAC) Inhibitors industry, and estimates the future trend of
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitor Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Histone Deacetylase (HDAC) Inhibitor Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-histone-deacetylase-hdac-inhibitor-market-research-report-2017-1541214 In this report, the global Histone Deacetylase (HDAC) Inhibitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented